TETEC AG

TETEC AG

Development of new methods for the treatment of complex damage to and disease of the human skeletal and locomotor system

TETEC was initially founded as a limited liability company (GmbH). In 2003, TETEC® was converted into a joint-stock company (AG). "TE" stands for tissue engineering and "TEC" for innovative technologies.

TETEC AG holds a manufacturing permit in accordance with §13 Para.1 German Drug Law (AMG) for its autologous cartilage cell products NOVOCART, NOVOCART 3D and NOVOCART Disc. NOVOCART is an autologous chondrocyte preparation while NOVOCARD 3D is a combination of autologous cartilage cells and a bi-phasic, three-dimensional, collagen-based matrix. NOVOCART 3D is ideal for the biological reconstruction of articular cartilage defects. NOVOCART Disc is a high-quality, autologous cell preparation for the biological reconstruction of partially-damaged intervertebral discs following a slipped disc.

ADCT (Autologous Disc Cell Transplantation; the transplantation of in chondrocytes from autologous disc tissue that have been cultured in vitro) is the only method that facilitates the biological reconstruction of partially-damaged disc tissue before widespread degeneration occurs. The cultured cartilage cells, isolated from the biopsy material, induce the desired biological reconstruction.

Category

Biotechnology

Activity Biomaterials, Development, Life Science, Medicine, Production, Cell Culture, Surgery

Management

Dr. C Gaissmaier
Dr. K. Maleck

Year of foundation

2000

Employees

80

Supervisory board

Prof. H. Hämmerle
Prof. H. P. Knaebel
Dr. J. Fritz

Bioprofile

Therapeutic use of adult mesenchymal stem cells (MSC) for the replacement of cartilage/bone.
Joint research project: Gelatin-based, smart biomaterials for cartilage regeneration

Certificates

ISO 9001, ISO 13485